<DOC>
	<DOC>NCT02372799</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.</brief_summary>
	<brief_title>Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male or Female outpatients between 717 years of age Primary diagnosis of Major Depressive Disorder (MDD) Children's Depression Rating ScaleRevised (CDRSR) score of 40 or greater Clinical Global ImpressionsSeverity (CGIS) score of 4 or greater Current (past 3 months) principal Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSMIVTR) based diagnosis of an axis disorder other than major depressive disorder (MDD) that is the primary focus of treatment. History of suicidal behavior, or requires precaution against suicide Not generally healthy medical condition Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>